(24/7 MARKET NEWS) – Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced, over the weekend, interim 10-month data from its ongoing Phase 1 clinical trial evaluating OTX-TKI, the Company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy and other retinal diseases.
The data was presented Saturday morning at the Angiogenesis, Exudation, and Degeneration 2023 Virtual Meeting, by Andrew A. Moshfeghi, MD, MBA, and can be accessed by visiting the scientific and medical presentations tab of the investor section of the Company’s investors.ocutx.com website.
Ocular Therapeutix is at $4.44, up $0.57 (14.72%), on 200 thousand premarket shares.
Its 52-week trading range is $2.57 to $6.525. If can break through the $4.50 resistance level, on strong volume, it could try to challenge the $5+ level.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.